Protalix shares dip as FDA poses new Gaucher drug query

Shares of Israel's Protalix Biotherapeutics slid 14 percent after the FDA bounced back its marketing application for a new Gaucher disease drug with a request for more information. The agency had some follow-up questions that focus on the manufacturing process, Protalix said in a release, and had not asked for more clinical or preclinical input.

Protalix (PLX) hastened to assure investors--who bid up the company stock as Genzyme floundered last year after it was forced to halt production of Cerezyme--that they could get the agency's questions answered in the second quarter. Genzyme reaps about $200,000 for a year's supply of Cerezyme.

At the end of January Protalix shares were fueled by a report that its drug--taliglucerase--was better than Cerezyme in penetrating the target cells. It also didn't hurt that Halman Aldubi began coverage of the company with a boldly bullish assessment that its shares could almost double in value in February. Earlier today, though, investors were of a different mindset, as Protalix's shares were trading down at around $6.07.

- check out the Protalix release
- here's the Reuters story

Suggested Articles

Inovio CEO J. Joseph Kim is undeterred by short sellers and other detractors who doubt his company can shuttle a COVID-19 DNA vaccine to market.

Adding entinostat to hormone therapy did not help patients with HR-positive, HER2-negative breast cancer live longer.

The data add to the evidence in support of the IL-6 drug ahead of a FDA decision to approve it in a rare disease served by Alexion’s Soliris.